<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624308</url>
  </required_header>
  <id_info>
    <org_study_id>2020-JS001-HPSCC</org_study_id>
    <nct_id>NCT04624308</nct_id>
  </id_info>
  <brief_title>Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC</brief_title>
  <official_title>Toripalimab Plus TPF Inductive Chemotherapy and Definitive Radiotherapy for Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Efficacy and Safety: a Phase II Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TPF is the standard regime of inductive chemotherapy for squamous carcinoma of head and neck.&#xD;
      If the primary tumor shrinks obviously (complete remission or &gt;75% partial remission )after&#xD;
      inductive chemotherapy, CCRT is suggested as the definitive therapy, for the tumor is&#xD;
      sensitive to chemotherapy. If the primary tumor shrinks a little or progresses after&#xD;
      inductive chemotherapy, operation is suggested as the definitive therapy to get a longer&#xD;
      survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inductive chemotherapy plus CCRT or operation is an option of organ preservation for patients&#xD;
      of hypopharyngeal carcinoma. Many clinical studies have demonstrated that inductive&#xD;
      chemotherapy plus CCRT achieved the same prognosis as total laryngectomy, and minimized the&#xD;
      damage of normal tissue. TPF is the standard regime of inductive chemotherapy for squamous&#xD;
      carcinoma of head and neck. If the primary tumor shrinks obviously (complete remission or&#xD;
      &gt;75% partial remission )after inductive chemotherapy, CCRT is suggested as the definitive&#xD;
      therapy, for the tumor is sensitive to chemotherapy. If the primary tumor shrinks a little or&#xD;
      progresses after inductive chemotherapy, operation is suggested as the definitive therapy to&#xD;
      get a longer survival. This is a prospective, phase II, cohort study. We designate TPF plus&#xD;
      Toripalimab as the inductive regime, expecting a higher complete remission rate and longer&#xD;
      PFS and OS. And we replace the CCRT with radiation plus Toripalimab to decrease the adverse&#xD;
      events of CCRT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>Complete remission rate 3 months after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>5 year</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>5 year</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>5 year</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Hypopharyngeal Neoplasm Malignant Primary</condition>
  <arm_group>
    <arm_group_label>TPF inductive chemotherapy plus Toripalimab and radiotherapy plus Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPF inductive chemotherapy plus Toripalimab for 3 cycles, and radiotherapy plus Toripalimab if the inductive treatment efficacy is CR or &gt;75%PR. If not, operation is suggested.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.</description>
    <arm_group_label>TPF inductive chemotherapy plus Toripalimab and radiotherapy plus Toripalimab</arm_group_label>
    <other_name>Tuoyi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18y ≤age≤65y;&#xD;
&#xD;
          2. ECOG：0-1；&#xD;
&#xD;
          3. Histology：squamous cell carcinoma, located in hypopharynx;&#xD;
&#xD;
          4. clinical stage: cT1N1-3M0、cT2-3N0-3M0，organ-preservation-intent regime is made after&#xD;
             multidisciplinary treatment(MDT) discussion. Efficacy evaluation will be made&#xD;
             according to RECIST 1.1 after inductive chemotherapy, and the following treatment will&#xD;
             be chosen according to the results of efficacy evaluation.&#xD;
&#xD;
          5. never received any previous treatment, including radiotherapy, chemotherapy, or immune&#xD;
             therapy, et al.&#xD;
&#xD;
          6. at least one measurable lesion (RECIST 1.1 criteria).&#xD;
&#xD;
          7. expected survival ≥6 months.&#xD;
&#xD;
          8. no contraindications of radiotherapy, chemotherapy and immune therapy.&#xD;
&#xD;
          9. functions of main organs A. WBC≥3.0x109 /L，ANC≥1.5x109/L B. HB≥90g/L C. PLT≥100x109 /L&#xD;
             D. serum albumin≥2.8g/dL E. TBil ≤1.5xULN，ALT、AST≤3.0xULN F. serum creatinine ≤1.5xULN&#xD;
             or creatinine clearance rate&gt;60mL/min（Cockcroft-Gault） G. APTT and INR ≤1.5xULN&#xD;
&#xD;
         10. contraception&#xD;
&#xD;
         11. voluntary and compliance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. other histology cancers located in hypopharynx.&#xD;
&#xD;
          2. synchronous or metachronous cancers located in other sites.&#xD;
&#xD;
          3. allergy to monoclonal antibody.&#xD;
&#xD;
          4. uncontrollable heart disease or symptoms.&#xD;
&#xD;
          5. uncontrollable infections.&#xD;
&#xD;
          6. fever of unknown origin&gt;38.5℃ during screening or before administration.&#xD;
&#xD;
          7. active autoimmune disease.&#xD;
&#xD;
          8. history of immunodeficiency disorders, including HIV.&#xD;
&#xD;
          9. active HBV or HCV.&#xD;
&#xD;
         10. history of interstitial lung disease.&#xD;
&#xD;
         11. active tuberculosis.&#xD;
&#xD;
         12. received any drugs listed below: A. received any study drug 4 weeks before first dose&#xD;
             of Toripalimab. B. received any anti-cancer drug 4 weeks before first dose of&#xD;
             Toripalimab. C. received any glucocorticoids （&gt;10mg prednison per day） 2 weeks before&#xD;
             first dose of Toripalimab.&#xD;
&#xD;
             D. received any cancer vaccine 4 weeks before first dose of Toripalimab. E. received&#xD;
             any operation or trauma 4 weeks before first dose of Toripalimab. F. recruited in&#xD;
             other study.&#xD;
&#xD;
         13. uncontrollable hypertension.&#xD;
&#xD;
         14. uncontrollable type 2 diabetes；&#xD;
&#xD;
         15. hemorrhagic tendency.&#xD;
&#xD;
         16. drug or alcoholic abuse.&#xD;
&#xD;
         17. woman during pregnancy or lactation period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Sun, MD</last_name>
    <phone>0086-10-88196217</phone>
    <email>lisaysun@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Sun, MD</last_name>
      <phone>010-88196217</phone>
      <email>lisaysun@139.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 31, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Sun Yan</investigator_full_name>
    <investigator_title>Principal Investigator, Chief of Head and Heck Group of Radiotherapy Department, Peking University Cancer Hospital, Peking University</investigator_title>
  </responsible_party>
  <keyword>hypopharyngeal carcinoma</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>inductive chemotherapy</keyword>
  <keyword>PD-1 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hypopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data is administered by Peking University Cancer Hospital, the investigators need to request related department for sharing IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

